Cervical Cancer Elimination

Myanmar

Cervical cancer is one of the most preventable cancers. However, in 2020, an estimated 341,800 women died from cervical cancer globally. The annual number of new cases of cervical cancer has been projected to increase from 570,000 to 700,000 between 2018 and 2030, with the annual number of deaths projected to increase from 311,000 to 400,000. Most of these deaths occurred in low- and lower-middle income countries (LMICs) due to inadequate access to cervical cancer prevention, screening and treatment.

In November 2020, the World Health Organization launched a Global Strategy to accelerate the elimination of cervical cancer as a public health problem. The Strategy proposes an elimination threshold of 4 cases per 100,000 women, achieved by implementing the triple intervention targets by 2030:

- 90% of girls fully vaccinated with the HPV vaccine by age 15.
- 70% of women screened with a high-performance test (such as the HPV test) by 35, and again by 45 years.
- 90% of women identified with cervical precancer or invasive cancer receive adequate treatment and care.

If this Strategy is implemented globally, a total of 74 million cervical cancer cases could be prevented and 62 million women’s lives could be saved over the next century. This Strategy also represents the most cost-effective approach across 95% of countries analyzed, and is expected to offer immense economic and societal benefits, with an estimated US $3.20 returned to the economy, rising to US $26.00 when societal benefits are incorporated, for every dollar invested through 2050 due to increases in women’s participation in the workforce.

In Myanmar, cervical cancer is the most common cancer in women, with 6,472 new cases (21.5 per 100,000 women) and 3,856 deaths (13.1 per 100,000 women) in 2018. The prevalence of HIV among females aged 15-49 years was 0.6% and an estimated 87% of women living with HIV were on treatment in 2018. It was predicted that without any intervention, a total of 293,721 women in Myanmar will die from cervical cancer by 2070 and 602,201 by 2120.

Pilot cervical cancer screening projects using visual inspection with acetic acid (VIA) have been undertaken in Myanmar, and in 2020, the HPV vaccine was introduced into the national immunization programme with Gavi support.

However, to reach the elimination targets, organized national programmes for both HPV vaccination and cervical cancer screening and treatment need to be implemented, with high coverage achieved across both, and competencies of health workforce will need to be strengthened across all three pillars (HPV vaccination, cervical screening and treatment) for long-term success on the path towards elimination.

Pillar 1: HPV Vaccination

The introduction of HPV vaccines into the national immunization programme is a crucial first step to be able to achieve a high coverage of HPV vaccination. Scale-up of HPV vaccination coverage could be facilitated by considering multisectoral delivery platforms, including a school-based strategy targeting adolescent females aged 9-14 years, or innovative community-based strategies. It is not cost-effective to vaccinate boys as well as girls. It is also important to secure sufficient and affordable HPV vaccines, through a concerted effort to negotiate for reasonable prices and with
international partnerships and support, including from Gavi. Improving monitoring systems and implementing vaccination registers are critical for ensuring that high coverage is met. Educating the community on the importance of HPV vaccination to prevent cervical cancer and having strategies to deal with misinformation are also important for maintaining confidence in the programme.

**Pillar 2: Cervical Cancer Screening**

Cervical cancer screening programmes represent the second pillar of the three-pronged Strategy. These screening programmes could be integrated with existing services such as primary care services, for instance by offering HPV testing at sexual health clinics, ante-natal care consultations, family planning consultations or women’s health clinics. Integrating cervical cancer screening with facilities that offer services for HIV control should be considered to ensure women at high risk of cervical cancer have access to cervical cancer screening. This would minimize unnecessary referrals and reduce transport costs and waiting time for women. Understanding social and cultural barriers will be create an environment where women feel comfortable attending screening visits.

**Pillar 3: Cervical Cancer Treatment**

Lastly, developing and implementing national cervical cancer management guidelines is essential to providing women with high quality cancer treatment and care.

The establishment of strong referral networks between all aspects of the cancer care spectrum is needed to ensure the timely management of patients and reduce loss-to-follow-up. Diagnosis, treatment, and monitoring of invasive cervical cancer will require high-quality pathology services and oncology services. Safe, effective, and timely surgery accompanied by supportive services such as anesthetic services and intensive care units are important for the treatment of early stage cancers.

Additionally, it is essential to provide information and education for women on the importance of cervical cancer screening, and potentially offering self-collection for HPV testing, or point-of-care HPV testing in rural areas, so that women who need pre-cancer treatment can be treated in the same visit. Screening scale-up should utilize clinically validated high sensitivity tests, and strengthening of laboratory services and quality assurance programmes will ensure the programme is effective. Implementing surveillance and monitoring systems are also critical for ensuring women are not lost to follow-up and for monitoring programme success nationally.

If the three pillars of elimination are established, Myanmar could avert over 472,000 deaths due to cervical cancer over the next century.

Furthermore, expanding access to radiotherapy units and access to chemotherapy services, as well as palliative care services, is crucial.

The Elimination Implementation Checklist on the final page summarizes the steps that countries should take to ensure the three pillars for elimination are successfully implemented and maintained over the longer term.
Table 1: Cervical cancer deaths averted, attributable to each pillar of the elimination strategy.

<table>
<thead>
<tr>
<th>Year</th>
<th>Vaccination</th>
<th>Screening &amp; pre-cancer treatment</th>
<th>Cancer treatment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020-2030</td>
<td>54</td>
<td>905</td>
<td>5,872</td>
<td>6,832</td>
</tr>
<tr>
<td>2020-2070</td>
<td>64,470</td>
<td>71,698</td>
<td>45,557</td>
<td>181,726</td>
</tr>
<tr>
<td>2020-2120</td>
<td>316,730</td>
<td>98,158</td>
<td>58,027</td>
<td>472,916</td>
</tr>
</tbody>
</table>

Prospects for Cervical Cancer Elimination in Myanmar

Concerted action now across all three elimination pillars is critical. The timing of impacts will vary, but action now will have substantial long-term impacts.

If all three elimination pillars are reached by 2030, a total of 6,832 cervical cancer deaths will be prevented by 2030, 181,726 deaths prevented by 2070 and 472,916 cervical cancer deaths by 2120 (Table 1).

Myanmar could eliminate cervical cancer by 2068.

The effects of HPV vaccination will be seen after a few decades (Figure 1). HPV vaccination would have limited impact before 2030, but the results will be seen in coming decades: HPV vaccination could prevent nearly 64,470 cervical cancer deaths by 2070, and 316,730 cervical cancer deaths by 2120 (Table 1).

The effects of cervical cancer screening and pre-cancer treatment will be seen mainly in the mid-term, after 2030 (Figure 1). Cervical screening would prevent an additional 905 cervical cancer deaths by 2030, 71,698 deaths by 2070 and 98,158 cervical cancer deaths by 2120 (Table 1).

Cervical cancer treatment scale-up will have immediate impacts on deaths averted (Figure 1). Scale-up of cancer treatment would prevent an additional 5,872 cervical cancer deaths by 2030, 45,557 deaths by 2070 and 58,027 cervical cancer deaths by 2120 (Table 1).

Myanmar is at a crucial stage in its efforts to prevent and treat cervical cancer, and a concerted strategic plan to accelerate the elimination of cervical cancer needs to be developed and implemented. There will be many challenges along the way, including vaccine and screening test supply and delivery challenges, human resource capacity and the infrastructure challenges associated with scale-up of invasive cancer diagnostics, treatment, and supportive and palliative care services. However, the tools and technology are now available; research has shown that elimination strategies are cost-effective and will prevent over 472,000 deaths over the next century. Both HPV vaccination and cervical cancer screening and treatment have been identified by WHO as best buys and are included in the list of national health plan recommendations by WHO. The elimination agenda is a component of the United Nations Global Strategy for Women’s, Children’s and Adolescent’s Health.

Achieving cervical cancer elimination in Myanmar will support several sustainable development goals (SDGs) and targets, including SDG 3 (good health and well-being), SDG 5 (gender equity) and SDG 10 (reducing inequalities). The implementation of HPV vaccination, cervical cancer screening and cancer treatment access will be facilitated by the full realization of universal health care in Myanmar, and collaboration with other sectors for sharing knowledge, financial resources and expertise in achieving the SDG goals will be crucial. Cervical cancer elimination is within our reach and we urge all stakeholders to support this effort by investing in the comprehensive approach as a national priority.

References

### Strategic actions to achieve elimination targets

#### 1 Develop a comprehensive costed National Cervical Cancer Elimination Strategy and seek endorsement among government, country leaders, policymakers, and communities

- [ ]

#### 2 Communication and public outreach

2.1 Develop a comprehensive communications strategy to accompany each component of the elimination strategy engaging health workers, community leaders, parents, teachers, and young people to maintain confidence in the programme and address stigma and misconceptions.

- [ ]

#### 3 National HPV vaccination programme

3.1 Introduce the HPV vaccine for girls aged 9-14 years into national immunization programme.

- [ ]

3.2 Secure sufficient and affordable HPV vaccine and ensure an adequate cold-chain system for vaccine storage and delivery is in place.

- [ ]

3.3 Achieve and maintain high coverage of HPV vaccination by identifying appropriate multi-sectoral vaccination delivery platforms.

- [ ]

3.4 Establish or improve monitoring systems or vaccination registers to enable measurement of coverage and vaccine schedule adherence.

- [ ]

#### 4 National cervical cancer screening and pre-cancerous treatment programme

4.1 Develop a national cervical cancer screening programme with clinical protocols for primary HPV testing and pre-cancer treatment, involving relevant stakeholders when appropriate.

- [ ]

4.2 Integrate screening and pre-cancer treatment into existing primary care and Universal Health Care (UHC) packages, including sexual and reproductive health services, HIV clinics, antenatal care.

- [ ]

4.3 Establish continuing professional development in-service programmes to build capacity of providers in cervical cancer screening and pre-cancer treatment.

- [ ]

4.4 Understand social, financial, cultural, societal, and structural barriers to accessing services and create an enabling environment for cervical cancer screening and pre-cancer treatment.

- [ ]

4.5 Strengthen laboratory capacity and quality assurance (QA) programmes and develop data systems that link laboratory information, screening registry data and other data systems (such as medical records and cancer registries).

- [ ]

#### 5 Invasive cancer treatment and palliative care

5.1 Develop and implement cervical cancer management guidelines and clinical protocols.

- [ ]

5.2 Establish effective referral pathways for women at all stages of care.

- [ ]

5.3 Strengthen pathology services, particularly at regional pathology centres and, if appropriate, make use of telepathology platforms to improve the capacity to interpret samples.

- [ ]

5.4 Expand surgical capacity through training programmes, and expand access to radiotherapy and chemotherapy services and strengthen oncology services.

- [ ]

5.5 Strengthen and integrate palliative care services by developing treatment plans that incorporate not only end-of-life care and pain relief, but also psychological and family support.

- [ ]

5.6 Optimize health workforce competencies throughout the continuum of care by establishing a long-term continuous training and education strategy for a multidisciplinary workforce.

- [ ]

5.7 Reduce cancer stigma by providing comprehensive support to enhance quality of life and address mental and sexual and reproductive health challenges faced by cancer survivors.

- [ ]

#### 6 Monitoring and evaluation

6.1 Strengthen governance and accountability of cervical cancer related programmes (HPV vaccination, cervical cancer screening, cancer treatment) and conduct regular reviews to ensure that national strategies, plans, and resource allocations reflect actual country needs.

- [ ]

6.2 Set country-specific targets, milestones, and indicators for monitoring and evaluating implementation of the National Cervical Cancer Elimination Strategy.

- [ ]

6.3 Improve current population-based cancer registries and develop new population-based cancer registries as needed to track the progress of the elimination targets.

- [ ]

6.4 Track patients throughout the continuum of services (screening, diagnosis and treatment).

- [ ]

---

*This checklist was developed based on the WHO strategy for cervical cancer elimination. For more guidance on the implementation of cervical cancer screening and treatment, see the WHO guide to strengthening cervical cancer prevention and the WHO guidelines for pre-cancer treatment.*